{"id":15883,"date":"2019-12-16T16:54:42","date_gmt":"2019-12-16T16:54:42","guid":{"rendered":"https:\/\/dejalex.com\/it\/2019\/12\/indagine-antitrust-usa-nei-confronti-dellindustria-generica-nuovi-sviluppi-e-possibili-accordi\/"},"modified":"2019-12-16T16:55:29","modified_gmt":"2019-12-16T16:55:29","slug":"indagine-antitrust-usa-nei-confronti-dellindustria-generica-nuovi-sviluppi-e-possibili-accordi","status":"publish","type":"post","link":"https:\/\/www.dejalex.com\/it\/2019\/12\/indagine-antitrust-usa-nei-confronti-dellindustria-generica-nuovi-sviluppi-e-possibili-accordi\/","title":{"rendered":"INDAGINE ANTITRUST USA NEI CONFRONTI DELL\u2019INDUSTRIA GENERICA. NUOVI SVILUPPI E POSSIBILI ACCORDI"},"content":{"rendered":"<p>Proseguono le indagini da parte delle autorit\u00e0 antitrust statunitensi nella maxi causa di cartello che coinvolge una ventina di industrie farmaceutiche generiche, tra le quali spiccano per importanza Teva Pharmaceutical Industries (Teva), Pfizer Inc. (Pfizer) e Sandoz Pharmaceuticals (Sandoz), facente parte del gruppo Novartis International AG (Novartis)&#8230;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-2114 aligncenter\" src=\"https:\/\/dejalex.com\/it\/wp-content\/uploads\/2019\/12\/Articolo_Indagine-antitrust-USA-nei-confronti-dellindustria-generica.-Nuovi-sviluppi-e-possibili-accordi.jpg\" alt=\"\" width=\"557\" height=\"789\" \/><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/dejalex.com\/it\/wp-content\/uploads\/2019\/12\/Articolo_Indagine-antitrust-USA-nei-confronti-dellindustria-generica.-Nuovi-sviluppi-e-possibili-accordi.pdf\" target=\"_blank\" rel=\"noopener\"><i  class=\"x-icon x-icon-download\" data-x-icon-s=\"&#xf019;\" aria-hidden=\"true\"><\/i> Scarica l&#8217;articolo<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[x_icon type=\"tag\"] Globally Minded, Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences<\/p>\n","protected":false},"author":3,"featured_media":220,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[338,370,319,422,307],"tags":[],"class_list":["post-15883","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-diritto-europeo-e-della-concorrenza","category-farmaceutico-e-life-sciences","category-globally-minded-it","category-pubblicazioni","category-roberto-jacchia-it"],"_links":{"self":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/posts\/15883","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/comments?post=15883"}],"version-history":[{"count":1,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/posts\/15883\/revisions"}],"predecessor-version":[{"id":15884,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/posts\/15883\/revisions\/15884"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/media\/220"}],"wp:attachment":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/media?parent=15883"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/categories?post=15883"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/tags?post=15883"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}